Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis.

Suppr

超能文献

作者信息

Narváez J, Díaz-Torné C, Juanola X, Geli C, Llobet J M, Nolla J M, Díaz-López C

出版信息

Ann Rheum Dis. 2009 Apr;68(4):607-8. doi: 10.1136/ard.2008.092106.

DOI:10.1136/ard.2008.092106

PMID:19286909

Abstract

摘要

相似文献

Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis.

Ann Rheum Dis. 2009 Apr;68(4):607-8. doi: 10.1136/ard.2008.092106.

Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans.比较儿童关节炎与风湿病研究联盟（CARRA）系统性幼年特发性关节炎共识治疗方案的初步研究。

Pediatr Rheumatol Online J. 2017 Apr 11;15(1):23. doi: 10.1186/s12969-017-0157-1.

Decreased expression of nicotinamide phosphoribosyltransferase in patients with juvenile idiopathic arthritis receiving methotrexate.接受甲氨蝶呤治疗的幼年特发性关节炎患者中烟酰胺磷酸核糖转移酶表达降低。

J Rheumatol. 2013 May;40(5):741-2. doi: 10.3899/jrheum.120639.

[Biologicals in the treatment of rheumatic diseases].[生物制剂在风湿性疾病治疗中的应用]

Dtsch Med Wochenschr. 2006 Oct 13;131(41):2279-85. doi: 10.1055/s-2006-951364.

Juvenile idiopathic arthritis: current and future treatment options.青少年特发性关节炎：当前及未来的治疗选择

Expert Opin Pharmacother. 2006 Mar;7(4):387-99. doi: 10.1517/14656566.7.4.387.

[Biological therapy treatment of juvenile idiopathic arthritis].[青少年特发性关节炎的生物治疗]

Ugeskr Laeger. 2008 Jun 9;170(24):2105-8.

Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept.英夫利昔单抗在对依那西普难治的全身型幼年特发性关节炎患者中的应用。

Clin Exp Rheumatol. 2005 Jul-Aug;23(4):545-8.

Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate.类风湿关节炎患者接受利妥昔单抗单药治疗与接受甲氨蝶呤联合治疗的临床结局及B细胞耗竭情况比较

Ann Rheum Dis. 2008 Nov;67(11):1648-9. doi: 10.1136/ard.2007.087023.

Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis.重复利妥昔单抗治疗方案治疗重症难治性幼年特发性关节炎的疗效和安全性。

Clin Rheumatol. 2011 Sep;30(9):1163-72. doi: 10.1007/s10067-011-1720-7. Epub 2011 Mar 8.

Treatment of juvenile idiopathic arthritis in the biologic age.生物时代的幼年特发性关节炎治疗。

Rheum Dis Clin North Am. 2013 Nov;39(4):751-66. doi: 10.1016/j.rdc.2013.05.004. Epub 2013 Jul 5.

引用本文的文献

Treatment of systemic juvenile idiopathic arthritis.全身性幼年特发性关节炎的治疗。

Nat Rev Rheumatol. 2023 Dec;19(12):778-789. doi: 10.1038/s41584-023-01042-z. Epub 2023 Nov 3.

Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives.难治性全身型幼年特发性关节炎：当前的挑战与未来展望。

Ann Med. 2022 Dec;54(1):1839-1850. doi: 10.1080/07853890.2022.2095431.

B Cells on the Stage of Inflammation in Juvenile Idiopathic Arthritis: Leading or Supporting Actors in Disease Pathogenesis?青少年特发性关节炎炎症阶段的B细胞：疾病发病机制中的主角还是配角？

Front Med (Lausanne). 2022 Apr 4;9:851532. doi: 10.3389/fmed.2022.851532. eCollection 2022.

Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders.Rituximab 治疗免疫介导性疾病的安全性和疗效的系统评价。

Front Immunol. 2019 Sep 6;10:1990. doi: 10.3389/fimmu.2019.01990. eCollection 2019.

Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom.在英国的一项队列研究中，评估了利妥昔单抗在儿童和青少年幼年特发性关节炎中的使用情况和疗效。

Rheumatology (Oxford). 2019 Feb 1;58(2):331-335. doi: 10.1093/rheumatology/key306.

Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.难治性幼年特发性关节炎：当前及未来的治疗选择

Paediatr Drugs. 2016 Apr;18(2):101-8. doi: 10.1007/s40272-016-0164-6.

Advances in the treatment of polyarticular juvenile idiopathic arthritis.多关节型幼年特发性关节炎的治疗进展

Curr Opin Rheumatol. 2015 Sep;27(5):505-10. doi: 10.1097/BOR.0000000000000206.

Treatment of juvenile idiopathic arthritis: a revolution in care.青少年特发性关节炎的治疗：护理领域的一场革命。

Pediatr Rheumatol Online J. 2014 Apr 23;12:13. doi: 10.1186/1546-0096-12-13. eCollection 2014.

[B-cell targeted therapy for children and adolescents with rheumatic diseases].[针对儿童和青少年风湿性疾病的B细胞靶向治疗]

Z Rheumatol. 2013 May;72(4):347-53. doi: 10.1007/s00393-012-1064-y.

Cost of biologics in the treatment of juvenile idiopathic arthritis: a factor not to be overlooked.生物制剂治疗幼年特发性关节炎的费用：不容忽视的因素。

Paediatr Drugs. 2013 Aug;15(4):271-80. doi: 10.1007/s40272-013-0023-7.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验